TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars or guiding principles represent the foundation on which we are realizing our mission as an organization: People Quality Health Care Outcomes Customer Focus Innovation and Efficiency.
  • Bausch Health Companies Inc. (TSX: BHC) Latest News

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Will Continue to Be a Loser in 2017

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was a loser in 2016 and will continue to be a loser in 2017 as…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Next Stop $10?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) remains a risky bet.

    Read more »

    The Motley Fool
    Investing

    Is Kevin O’Leary Right About Valeant Pharmaceuticals Intl Inc.?

    Many investors are quite bearish on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), including Kevin O'Leary. Is Mr. Wonderful on to something…

    Read more »

    The Motley Fool
    Investing

    Making the Case for Valeant Pharmaceuticals Intl Inc.: Why it’s Not Worth it Yet

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock has been in shambles in 2016, plummeting more than 83%, but there is reason…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Is This Stock Worth a Contrarian Shot for 2017?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a seriously unloved stock. Is it finally time to buy?

    Read more »

    Investing

    Will Canopy Growth Corp. Crash as Hard as Valeant Pharmaceuticals Intl Inc.?

    Canopy Growth Corp. (TSX:CGC) has been falling hard over the last week. Will this company face the same fate as…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Has This Stock Finally Hit Bottom?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is getting a nice post-election bounce. Is this the time to buy?

    Read more »

    The Motley Fool
    Investing

    Why Bill Ackman Should Give Up on Valeant Pharmaceuticals Intl Inc.

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported a horrible quarter, and the stock responded by dropping. Bill Ackman still believes in…

    Read more »

    Investing

    3 TSX “Loser” Stocks to Bet on

    A total of 32 TSX stocks are down by more than 5% year-to-date, including Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), the…

    Read more »

    Investing

    Long-Term Investors: Valeant Pharmaceuticals Intl Inc. Looks to Ease Debt Burden

    Valeant Pharmaceuticals Intl Inc.'s (TSX:VRX)(NYSE:VRX) sale of its Salix drug business has the potential for great long-term gains for investors…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Drops After Q3 Results Disappoint

    Troubles continue for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) as the company posts worse than expected results.

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc. After its 22% Plunge?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) took a huge hit in its latest earnings report, and the stock responded by dropping…

    Read more »